TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial

2024-516182-37-01 Protocol TALASUR Therapeutic exploratory (Phase II) Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 15 sites · Protocol TALASUR

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Authorised, recruitment pending
Participants planned 45
Countries 1
Sites 15

Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma

Key facts

Sponsor
Centre Francois Baclesse
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2024-12-06
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516182-37-01
EudraCT number
2020-001105-24
ClinicalTrials.gov
NCT04678362

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma

VersionLevelCodeTermSystem organ class
21.0 LLT 10046721 Urothelial carcinoma bladder stage III 10029104
21.0 LLT 10046722 Urothelial carcinoma bladder stage IV 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Francois Baclesse

Sponsor organisation
Centre Francois Baclesse
Address
3 Avenue Du General Harris, Cs 45026 Cs 45026
City
Caen Cedex 5
Postcode
14076
Country
France

Scientific contact point

Organisation
Centre Francois Baclesse
Contact name
GRELLARD Jean-Michel

Public contact point

Organisation
Centre Francois Baclesse
Contact name
GRELLARD Jean-Michel

Locations

1 EU/EEA country · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 45 15
Rest of world 0

Investigational sites

France

15 sites · Authorised, recruitment pending
Centre Francois Baclesse
Oncology, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5
Oncopole Claudius Regaud
Oncology, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Hopital Tenon
Oncology, 4 Rue De La Chine, 75970, Paris Cedex 20
Centr Georges Francois Leclerc
Oncology, 1 Rue Professeur Marion, 21000, Dijon
Institut Paoli Calmettes
Oncology, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Centre Jean Perrin
Oncology, 58 Rue Montalembert, 63000, Clermont-Ferrand
Hospices Civils De Lyon
Oncology, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Centre Leon Berard
Oncology, 28 Rue Laennec, 69008, Lyon
Institut De Cancerologie De L Ouest
Oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Centre De Lutte Contre Le Cancer Eugene Marquis
Oncology, Avenue La Bataille Flandre Dunkerque, Cs 44229, Rennes Cedex
Groupe Hospitalier Diaconesses Croix Saint Simon
Oncology, 125 Rue D Avron, 75020, Paris
CHU Besancon
Oncology, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex
Centre Antoine Lacassagne
Oncology, 33 Avenue De Valombrose, 06189, Nice Cedex 2
Institut De Cancerologie De L Ouest
Oncology, 15 Rue Andre Boquel, 49100, Angers
Centre Hospitalier Regional Et Universitaire De Brest
Oncology, 2 Avenue Marechal Foch, 29200, Brest

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-09 France Acceptable
2024-09-25
2024-12-06